Free Cash Flow Chart

View Free Cash Flow for PGEN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow Chart
Start Trial

Historical Free Cash Flow Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -115.22M
March 31, 2026 -116.96M
December 31, 2025 -89.83M
September 30, 2025 -75.62M
June 30, 2025 -69.78M
March 31, 2025 -75.26M
December 31, 2024 -76.76M
September 30, 2024 -84.30M
June 30, 2024 -77.93M
March 31, 2024 -68.36M
December 31, 2023 -68.47M
September 30, 2023 -67.10M
June 30, 2023 -75.25M
March 31, 2023 -68.15M
December 31, 2022 -69.97M
September 30, 2022 -71.88M
June 30, 2022 -65.78M
March 31, 2022 -65.98M
December 31, 2021 -63.02M
September 30, 2021 -63.59M
June 30, 2021 -64.33M
March 31, 2021 -71.05M
December 31, 2020 -84.55M
September 30, 2020 -103.44M
June 30, 2020 -118.33M
Date Value
March 31, 2020 -149.95M
December 31, 2019 -173.81M
September 30, 2019 -185.58M
June 30, 2019 -188.24M
March 31, 2019 -179.92M
December 31, 2018 -165.83M
September 30, 2018 -165.10M
June 30, 2018 -163.94M
March 31, 2018 -160.44M
December 31, 2017 -150.80M
September 30, 2017 -138.56M
June 30, 2017 -128.28M
March 31, 2017 -103.78M
December 31, 2016 -87.86M
September 30, 2016 -42.81M
June 30, 2016 33.13M
March 31, 2016 23.56M
December 31, 2015 22.92M
September 30, 2015 3.265M
June 30, 2015 -54.60M
March 31, 2015 -48.48M
December 31, 2014 -26.23M
September 30, 2014 -26.49M
June 30, 2014 -34.74M
March 31, 2014 -34.25M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Geron Corp. -114.76M
Neurocrine Biosciences, Inc. 812.00M
Elicio Therapeutics, Inc. -37.71M
Agenus, Inc. -98.50M
Amgen, Inc. 10.18B